Source: Annual Congress 2006 - Miscellaneous respiratory infections I
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
R. Cernat, L. Butnaru, T. Mihaescu (Iasi, Romania). Diagnosed value of nonproteic sulphur in pulmonary affection. Eur Respir J 2006; 28: Suppl. 50, 4214

Member's Comments

No comment yet.

Related content which might interest you: Diagnostic value of nonproteic sulphur in pulmonary infections Source: Eur Respir J 2006; 28: Suppl. 50, 4s Year: 2006 Iron deficiency in pulmonary arterial hypertension: A matter of definition! Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Impact of specific organic exposure on the prognosis in Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Effects of hydrogen sulfide on ozone-induced features of chronic obstructive pulmonary disease Source: International Congress 2015 – Occupational and environmental effects: in vitro and animal models Year: 2015 Pulmonary hypertension in renal dialysis patients - A matter of water Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Pulmonary hemodynamics and gasometric parameters associated with exercise induced oxygen desaturation in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Pulmonary siderosis as a cause of systemic iron overload Source: International Congress 2015 – Occupational disease: clinical cases and series Year: 2015 Diffusing capacity for carbon monoxide (DLco) may predict appearance of pulmonary hypertension in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Endogenous hydrogen sulfide in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 440s Year: 2005 Incorporation into lipid nanoparticles extends the duration of activity of treprostinil in an acute hypoxia rat model of pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Nitrogen dioxide increases the risk of mortality in idiopathic pulmonary fibrosis Source: Eur Respir J, 57 (5) 2001877; 10.1183/13993003.01877-2020 Year: 2021 Metabolic dysfunction associated with redox imbalance in pulmonary hypertension: Effects of the prolonged sildenafil use Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 The evolution of effort tolerance and body composition in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Effect of pulmonary hemodynamics on the prognosis of patients with emphysematous COPD after LVRS Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 The diagnostic value of exhaled carbon monoxide and arterial carboxyhaemoglobin measurements in chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 408s Year: 2006 Role of inhaled antioxidants in chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 717s Year: 2005 Exhaled volatile organic compounds in idiopathic pulmonary fibrosis and disease progression Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis Year: 2020 Prognostic value of predicted 6MWD in PAH Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Oral iron supplementation with ferric maltol in patients with pulmonary hypertension Source: Eur Respir J, 56 (5) 2000616; 10.1183/13993003.00616-2020 Year: 2020 No effect of baseline diffusing capacity of lung for carbon monoxide on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016